A simple and rapid method to determine the zygosity of uPA-transgenic SCID mice by Meuleman, Philip et al.
Biochemical and Biophysical Research Communications 308 (2003) 375–378
www.elsevier.com/locate/ybbrc
BBRCA simple and rapid method to determine the zygosity
of uPA-transgenic SCID mice
P. Meuleman, P. Vanlandschoot, and G. Leroux-Roels*
Center for Vaccinology, Ghent University, De Pintelaan 185, Ghent 9000, Belgium
Received 7 July 2003Abstract
Successful transplantation of xenogeneic hepatocytes into uPA-transgenic SCID mice depends on the zygosity of the recipient
mice. Normally, the diﬀerence between homozygous and heterozygous animals is determined via a quantitative Southern blot. We
sequenced a part of the mouse genome that is eliminated upon integration of the transgene in the genome. Based on that sequence
we developed a multiplex PCR that allows the unambiguous discrimination of negative, heterozygous, and homozygous uPA-
transgenic SCID mice in a single day procedure. The speed of the procedure is an essential quality because transplantation of
xenogeneic hepatocytes into uPA-SCID mice should be done as soon as possible after birth.
 2003 Elsevier Inc. All rights reserved.
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hepatitis C virus (HCV) are major health problems.
Worldwide chronic infections with HBV and HCV aﬀect
an estimated 350 and 170 million people, respectively,
and are causing over a million deaths annually [1]. In
the past two decades major progress has been made in
the prevention and treatment of these infections but the
search for more eﬃcacious, tolerable, and aﬀordable
treatments for both ailments as well as the quest for a
vaccine for HCV go on. This research is hampered by
the lack of simple in vitro culture systems and reliable
small animal models. Both HBV and HCV have a very
narrow tropism and only man and chimpanzee are
natural hosts of these viruses. Ethical and ﬁnancial
constraints limit the use of chimpanzees for biomedical
research in general and hepatitis-related research in
particular. Therefore a small animal model to study
HBV and HCV is badly needed. Mice or rats are the
prime candidates to create such a model but the strin-
gent tropism of HBV and HCV imposes that hepato-
cytes from man or chimpanzee are transferred in these
rodents. To allow the survival and expansion of xeno-* Corresponding author. Fax : +32-9-240-63-11.
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animal must provide an environment that is permissive
for the engraftment and the expansion of the liver cells.
Both criteria are met in an immune deﬁcient animal that
suﬀers from a severe liver disease. An animal with both
ailments is not available but can be created by crossing
the Alb-uPA transgenic mouse with a severely immune
deﬁcient mouse strain such as the nude (nu/nu), the
SCID/beige, or the RAG= mouse [2–4].
The Alb-uPA transgenic mouse, developed in 1990 by
Heckel et al. [5] to study plasminogen hyperactivation
and therapeutic protocols to prevent bleeding, contains
a tandem repeat of four murine uPA genes under the
control of an albumin promoter. The transgene over-
expression results in profound hypoﬁbrinogenemia and
accelerated hepatocyte death. Homozygous animals can
be rescued by transplantation of normal hepatocytes
from mouse [6,7], rat [2], woodchuck [3] or man [4,8]
which undergo rapid proliferation to replace the dying
hepatocytes. Transplants of hepatocytes from species
susceptible to hepatitis viruses can be infected with the
homologous hepatitis virus. This was ﬁrst accomplished
with woodchuck hepatocytes infected with the wood-
chuck hepatitis virus [3] and more recently with human
hepatocytes which could be infected with HVB [8] and
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spontaneously lose the transgene at low frequency and
the ensuing ‘rescued’ mouse hepatocytes then repopulate
the liver [9]. For this reason heterozygous animals are
inferior recipients of xenogeneic hepatocyte grafts
compared to uPA homozygous mice. A rapid and reli-
able screening method to discriminate homozygous
from heterozygous transgenic mice is therefore impor-
tant for successful hepatocyte transplantation.
Initially this analysis of zygosity was performed by
quantitative comparison of the Southern blot signal
produced by probes for an endogenous gene and the
transgenic uPA gene [2]. This method is time consuming
and may generate ambiguous results. Rhim et al. also
noted that the insertion of the uPA transgene into the
mouse genome resulted in the deletion of endogenous
DNA at the integration site. These investigators picked-
up part of this sequence in plasmid p3371C and used this
as a probe to analyze the genotype of the animals. Using
a multiplex PCR based on this deleted endogenous se-
quence we designed a fast and reliable assay that allows
for the unambiguous determination of the zygosity of
the transgenic animals.Fig. 1. Map of plasmid p3371C containing a 2 kb part of the mouse
genome which has been deleted at the uPA transgene integration site.
The grey bar represents a known sequence which was used as the
starting point for the sequencing reactions. All unknown parts are
represented by a black bar. Enzymatic digestion of plasmid p3371C
with BamHI produces a 664 bp fragment which was previously used as
a probe for Southern blotting.Materials and methods
Breeding of the uPA-SCID mice. B6SJL-TgN(Alb1Plau)144Bri
mice were back-crossed on CBySmn.CB17-Prkdcscid mice. Both strains
were purchased from the Jackson Laboratories (Bar Harbor, Maine,
USA). Screening for the SCID background was done with an in-house
mouse IgM sandwich Elisa. Screening for the uPA transgene was done
by PCR, initially using the genotyping protocol described by the
Jackson Laboratories [10] and subsequently by the in-house method
described herein. All mice were bred and handled under speciﬁc
pathogen free (SPF) conditions in the SCID mouse facility of the
Department of Clinical Chemistry, Microbiology and Immunology,
Ghent University.
Ampliﬁcation, isolation, and sequencing of plasmid p3371C. ‘Top 10’
Escherichia coli cells (Invitrogen, Merelbeke, Belgium) were trans-
formed with plasmid p3371C (kindly provided by Dr. R. Palmiter) by
heat shock and grown overnight on LB-plates containing Ampicillin.
Resulting colonies were resuspended in LB-broth containing ampicillin
and incubated overnight at 37 C on a shaking platform. Cells were
centrifuged and plasmid was isolated with a HiSpeed Plasmid puriﬁ-
cation kit (Qiagen, Hilden, Germany) according to the manufacturer’s
protocol.
Plasmid p3371C was then sequenced with an ABI 310 sequencer
(Applied Biosystems, Lennik, Belgium). Brieﬂy, 500 ng plasmid,
3.2 pmol primer, and 8 ll of the Terminator Ready Reaction Mix
(Applied Biosystems, Lennik, Belgium) were denatured at 90 C for
30 s. Annealing (15 s at 50 C) and polymerization (4min at 60 C) were
repeated for 25 cycles. The resulting product was then puriﬁed using
ethanol/sodium acetate precipitation and analyzed on the sequencer.
Isolation of mouse genomic DNA. Genomic DNA was extracted
from the mouse tail using the Nucleospin Tissue Kit (BD Biosciences
Clontech, Erembodegem, Belgium) according to the manufacturer’s
protocol. Brieﬂy, tissue from the mouse tail was digested with Pro-
teinase K at 56 C for 3 h or until the sample was completely lysed.
After addition of a chaotropic agent the samples were incubated for
10min at 70 C. Then ethanol was added and the sample was loaded on
the Nucleospin columns and centrifuged for 1min at 11,000g. Thecolumn containing the trapped DNA was washed twice to remove any
contaminating proteins and other cellular debris. After contaminants
were spun through the ﬁlter, nucleic acids were eluted in 100ll of a
Tris-buﬀered solution. All enzymes and buﬀers were provided by the
manufacturer.
PCR. The PCR mix consists of 49 ll of thermophilic DNA poly-
merase buﬀer supplemented with 200lM dNTPs (Roche Diagnostics,
Vilvoorde, Belgium), 2.5mM MgCl2, 1lM of each primer, and 2.5U
Taq DNA polymerase (Promega, Leiden, The Netherlands). To this
mixture 1 ll of mouse genomic DNA was added. The PCR cycling
proﬁle was as follows: an initial denaturation step of 5min at 94 C was
followed by 30 cycles of 30 s denaturation at 94 C, 30 s primer an-
nealing at 62 C, and 30 s primer extension at 72 C. To promote com-
pletion of partial extension, the samples were held at 72 C for 5min.
The samples were then stored on ice until analysis on a 2.5% agarose gel.Results
Sequencing of plasmid p3371C
Rhim et al. [2] noted that the insertion of the uPA
transgene into the mouse genome resulted in the deletion
of endogenous DNA at the integration site. These in-
vestigators picked up part of this sequence in plasmid
p3371C (Fig. 1) and used the BamHI-fragment of this
region as a probe for detection via Southern blotting.
The sequence of the deleted region was unknown but
part of the plasmid has been sequenced. Starting from
this known sequence we performed serial overlapping
sequence reactions until we completely elucidated the
code of the deleted region. All the known restriction
sites inside p3371C were used as positive markers during
sequencing. The BamHI fragment (underlined in Fig. 1),
previously reported to be approximately 550 bp long,
consisted of the following 664 bp long sequence:
Fig. 2. Multiplex PCR to determine the zygosity of uPA-transgenic
mice. Mouse genomic DNA isolated from an uPA= (lane 2), uPAþ=
(lane 3), and uPAþ=þ (lane 4) SCID mouse was used as a template. The
301 bp product is only present in negative and heterozygous animals.
The ampliﬁcation product from the transgene itself (151 bp) is only
absent in uPA= animals. A control ampliﬁcation product (226 bp)
appears in all samples. All samples were compared to DNA molecular
weight marker XIII (Roche, Vilvoorde, Belgium) run in lane 1.
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GACACTTACTGATGCTATGGTGAATATTCTCTC
ATTATAAGGGTGACAGAAATAAGAGAAGAAT
TTACATAAAAAGTAAAAGGAACAATGAGTTT
AAAGCAGGGGAGTGTATCCACAGTTGAAATA
ACTACATTTGTCCTTTAAAACGTGGAATTAATC
TTTCTCTTCTCTTGCCCTCTCACATCATTGAATT
TTGCATATTAAGATATTTGCATGTCCAAGAAG
CAGCTGTTTTTGGAAACTGTTATACTTTCTACT
TTTCTCCATTGCTACTCCAATTGCAAAGCACAT
CATCACACAATGTGTGAATGATCCAGAGAGTC
TGATAGCATATCTCCCAAAGGCAGTCATTTCA
AAACTCTAGACAATCACCATCTGCATTGCATG
GGCCAGATTTCAAACAGGAGGCTCAAAGTAG
ACTCTGGAAATTTGCTGCTGTTGGCTGTCTTG
AGGGTCTCAATTGTAGATTCATTTCTCCAAACT
ATTGGAAGAATCTATTAATAGGAAAATTAACT
TAAAAACACAATTGATAATACCTCTCTTTTTTT
TAAAGTGAATTGGACCTTGTGTATTGCACAGA
CAGTAAGTTATGAATTTACCAAGACTTAGAAT
TCCTGCAGCCCGGGGGATCC.
Multiplex PCR
Based on the sequence of the deleted region and the
nature of the transgene cassette we developed a multi-
plex PCR based on three primer pairs.
Primer pair one, ApoA#1: 50-CATCTCGCACCTTT
AGCCAT-30 and ApoA#2: 50-TCTCTGTGCCCAG
GAAGGTA-30, is a control primer pair amplifying a
226 bp region of the mouse Apolipoprotein A1-gene.
This is a control primer pair that should always result in
a positive signal.
Primer pair two, uPA#1: 50-CATCCCTGTGACCC
CTCC-30 and uPA#2: 50-CTCCAAAACCACCCCCC
TC-30, ampliﬁes a 151 bp region within the 30-untrans-
lated region of the human growth hormone which is
present in the transgene cassette. This PCR product
allows us to discriminate between uPA negative and
positive animals.
The ampliﬁcation product of primer pair three,
uPA#3: 50-TTCTCTTCTCTTGCCCTCTCACA-30 and
uPA#4: 50-TTGAGACCCTCAAGACAGCCA-30 (both
underlined in the above shown sequence), is 301 bp large
and is the product of a region within the mouse genome
which was deleted when the transgene had entered.
The combination of the three above-mentioned pri-
mer pairs allowed us to determine unambiguously the
zygosity of the transgenic animals. Fig. 2 clearly shows
that in case of a uPA negative animal (lane 2) two bands
appear (226 and 301 bp). Because the transgene is absent
the 151 bp band is not present. Lane 4 shows the PCR
products of a homozygous uPA animal. Here also only
two bands are visible, the 226 control band and the
151 bp transgene band. There is no ampliﬁcation prod-
uct from primer set uPA#3 and #4 because the trans-gene has been inserted in both copies of the
chromosome. In case of a uPA heterozygous animal
(lane 3) all three bands appear. Heterozygous animals
still have one chromosome left where the endogenous
DNA has not been deleted, explaining the presence of a
301 bp product. This clearly demonstrates the simplicity
and the clarity of this method.Discussion
The need for an aﬀordable, reliable, and ethically
acceptable in vivo model to study HBV and HCV in-
fections is high. The uPA-mouse model ﬁrst described in
1990 represents one of the most promising tools to
create this research tool. uPA-transgenic mice bred on
an immune incompetent background like SCID, SCID/
beige or RAG= allow a repopulation of the sick liver
by allogeneic and xenogeneic hepatocytes. When trans-
planted with human hepatocytes these animals become
susceptible to infections with HBV and HCV [4,8].
However, the outcome of the xenogeneic liver cell graft
in these animals is largely dependent on the zygosity of
the uPA transgene in these animals. Whereas the sur-
vival and expansion of the liver cell graft is poor in
heterozygous mice, an excellent and sustained engraft-
ment is observed in homozygous animals. Since the
success of the transplantation increases when the donor
hepatocytes are introduced early after birth, preferably
at the age of one to two weeks, a fast and unambiguous
method to determine the zygosity of the animals is very
important. We designed a one day method based on the
loss of a small portion of the mouse genome as a con-
sequence of the transgene integration. We have
sequenced this region and used selected fragments from
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PCRs, one to detect the mouse Apo A1 region and one
to detect the uPA transgene itself, this single tube PCR
method meets the requirements mentioned above.
A search in the mouse genome database revealed
that a region homologous (p ¼ 8, 9E-58) to the deleted
sequence was located on chromosome 10, indicating
that this is the integration site. Finally it must be
stressed that with this method it is impossible to mis-
classify a negative or a heterozygous uPA mouse as a
homozygous animal because the screening method is
based on the absence of a signal. Any possible con-
tamination of uPAþ=þ chromosomal DNA with, e.g.,
wild type DNA will result in a heterozygous result. This
method thus prevents the occurrence of such errors and
as a consequence thereof the waste of very scarce and
valuable hepatocytes in erroneous transplantations.Acknowledgment
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